209 related articles for article (PubMed ID: 28811976)
1. Long-lived pancreatic ductal adenocarcinoma slice cultures enable precise study of the immune microenvironment.
Jiang X; Seo YD; Chang JH; Coveler A; Nigjeh EN; Pan S; Jalikis F; Yeung RS; Crispe IN; Pillarisetty VG
Oncoimmunology; 2017; 6(7):e1333210. PubMed ID: 28811976
[TBL] [Abstract][Full Text] [Related]
2. Organotypic slice cultures of pancreatic ductal adenocarcinoma preserve the tumor microenvironment and provide a platform for drug response.
Lim CY; Chang JH; Lee WS; Lee KM; Yoon YC; Kim J; Park IY
Pancreatology; 2018 Dec; 18(8):913-927. PubMed ID: 30292644
[TBL] [Abstract][Full Text] [Related]
3. Establishment of Slice Cultures as a Tool to Study the Cancer Immune Microenvironment.
Jiang X; Seo YD; Sullivan KM; Pillarisetty VG
Methods Mol Biol; 2019; 1884():283-295. PubMed ID: 30465211
[TBL] [Abstract][Full Text] [Related]
4. Mobilization of CD8
Seo YD; Jiang X; Sullivan KM; Jalikis FG; Smythe KS; Abbasi A; Vignali M; Park JO; Daniel SK; Pollack SM; Kim TS; Yeung R; Crispe IN; Pierce RH; Robins H; Pillarisetty VG
Clin Cancer Res; 2019 Jul; 25(13):3934-3945. PubMed ID: 30940657
[TBL] [Abstract][Full Text] [Related]
5. T-cell programming in pancreatic adenocarcinoma: a review.
Seo YD; Pillarisetty VG
Cancer Gene Ther; 2017 Mar; 24(3):106-113. PubMed ID: 27910859
[TBL] [Abstract][Full Text] [Related]
6. Expression and role of the immune checkpoint regulator PD-L1 in the tumor-stroma interplay of pancreatic ductal adenocarcinoma.
Daunke T; Beckinger S; Rahn S; Krüger S; Heckl S; Schäfer H; Wesch D; Pilarsky C; Eckstein M; Hartmann A; Röcken C; Wandmacher AM; Sebens S
Front Immunol; 2023; 14():1157397. PubMed ID: 37449210
[TBL] [Abstract][Full Text] [Related]
7. Protocol to culture and image pancreatic ductal adenocarcinoma tumor slices to study T cell migration.
Rodríguez-Merced NJ; Callaway MK; Provenzano PP
STAR Protoc; 2023 Mar; 4(1):102135. PubMed ID: 36861840
[TBL] [Abstract][Full Text] [Related]
8. The prognostic impact of programmed cell death ligand 1 and human leukocyte antigen class I in pancreatic cancer.
Imai D; Yoshizumi T; Okano S; Uchiyama H; Ikegami T; Harimoto N; Itoh S; Soejima Y; Aishima S; Oda Y; Maehara Y
Cancer Med; 2017 Jul; 6(7):1614-1626. PubMed ID: 28602029
[TBL] [Abstract][Full Text] [Related]
9. Activating Immune Recognition in Pancreatic Ductal Adenocarcinoma via Autophagy Inhibition, MEK Blockade, and CD40 Agonism.
Jiang H; Courau T; Borison J; Ritchie AJ; Mayer AT; Krummel MF; Collisson EA
Gastroenterology; 2022 Feb; 162(2):590-603.e14. PubMed ID: 34627860
[TBL] [Abstract][Full Text] [Related]
10. Intratumoral Cell Neighborhoods Coordinate Outcomes in Pancreatic Ductal Adenocarcinoma.
Wattenberg MM; Colby S; Garrido-Laguna I; Xue Y; Chang R; Delman D; Lee J; Affolter K; Mulvihill SJ; Beg MS; Wang-Gillam A; Wade JL; Guthrie KA; Chiorean EG; Ahmad SA; Lowy AM; Philip PA; Sohal DPS; Beatty GL
Gastroenterology; 2024 Jun; 166(6):1114-1129. PubMed ID: 38244727
[TBL] [Abstract][Full Text] [Related]
11. CD40 Agonists Alter the Pancreatic Cancer Microenvironment by Shifting the Macrophage Phenotype toward M1 and Suppress Human Pancreatic Cancer in Organotypic Slice Cultures.
Lim CY; Chang JH; Lee WS; Kim J; Park IY
Gut Liver; 2022 Jul; 16(4):645-659. PubMed ID: 34933280
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of PAK1 suppresses pancreatic cancer by stimulation of anti-tumour immunity through down-regulation of PD-L1.
Wang K; Zhan Y; Huynh N; Dumesny C; Wang X; Asadi K; Herrmann D; Timpson P; Yang Y; Walsh K; Baldwin GS; Nikfarjam M; He H
Cancer Lett; 2020 Mar; 472():8-18. PubMed ID: 31857154
[TBL] [Abstract][Full Text] [Related]
13. PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors.
Soares KC; Rucki AA; Wu AA; Olino K; Xiao Q; Chai Y; Wamwea A; Bigelow E; Lutz E; Liu L; Yao S; Anders RA; Laheru D; Wolfgang CL; Edil BH; Schulick RD; Jaffee EM; Zheng L
J Immunother; 2015 Jan; 38(1):1-11. PubMed ID: 25415283
[TBL] [Abstract][Full Text] [Related]
14. Adding combination immunotherapy consisting of cancer vaccine, anti-PD-1 and anti-CSF1R antibodies to gemcitabine improves anti-tumor efficacy in murine model of pancreatic ductal adenocarcinoma.
Saung MT; Zheng L
Ann Pancreat Cancer; 2019 Dec; 2():. PubMed ID: 32405624
[TBL] [Abstract][Full Text] [Related]
15. Combining the Specific Anti-MUC1 Antibody TAB004 and Lip-MSA-IL-2 Limits Pancreatic Cancer Progression in Immune Competent Murine Models of Pancreatic Ductal Adenocarcinoma.
Dréau D; Moore LJ; Wu M; Roy LD; Dillion L; Porter T; Puri R; Momin N; Wittrup KD; Mukherjee P
Front Oncol; 2019; 9():330. PubMed ID: 31114758
[TBL] [Abstract][Full Text] [Related]
16. Pancreatic ductal adenocarcinoma contains an effector and regulatory immune cell infiltrate that is altered by multimodal neoadjuvant treatment.
Shibuya KC; Goel VK; Xiong W; Sham JG; Pollack SM; Leahy AM; Whiting SH; Yeh MM; Yee C; Riddell SR; Pillarisetty VG
PLoS One; 2014; 9(5):e96565. PubMed ID: 24794217
[TBL] [Abstract][Full Text] [Related]
17. Hypoxia as a barrier to immunotherapy in pancreatic adenocarcinoma.
Daniel SK; Sullivan KM; Labadie KP; Pillarisetty VG
Clin Transl Med; 2019 Apr; 8(1):10. PubMed ID: 30931508
[TBL] [Abstract][Full Text] [Related]
18. Distinct Stromal and Immune Features Collectively Contribute to Long-Term Survival in Pancreatic Cancer.
Sadozai H; Acharjee A; Eppenberger-Castori S; Gloor B; Gruber T; Schenk M; Karamitopoulou E
Front Immunol; 2021; 12():643529. PubMed ID: 33679807
[No Abstract] [Full Text] [Related]
19. Combination immunotherapy for pancreatic cancer: challenges and future considerations.
Gössling GCL; Zhen DB; Pillarisetty VG; Chiorean EG
Expert Rev Clin Immunol; 2022 Nov; 18(11):1173-1186. PubMed ID: 36045547
[TBL] [Abstract][Full Text] [Related]
20. Treatment of pancreatic ductal adenocarcinoma with tumor antigen specific-targeted delivery of paclitaxel loaded PLGA nanoparticles.
Wu ST; Fowler AJ; Garmon CB; Fessler AB; Ogle JD; Grover KR; Allen BC; Williams CD; Zhou R; Yazdanifar M; Ogle CA; Mukherjee P
BMC Cancer; 2018 Apr; 18(1):457. PubMed ID: 29685122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
